Literature DB >> 24779451

TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy.

Sami Raatikainen1, Sirpa Aaltomaa, Jorma J Palvimo, Vesa Kärjä, Ylermi Soini.   

Abstract

OBJECTIVE: The aim of this study was to determine whether TWIST and androgen receptor (AR) expression can predict the outcome in radical prostatectomy (RP) patients.
MATERIAL AND METHODS: Samples from different tumour areas of 181 prostate cancer patients were analysed for TWIST and AR expression, and the results were correlated with known clinicopathological data and biochemical recurrence-free survival (BFS).
RESULTS: TWIST overexpression in the margin area of the tumour (M-TWIST) was related to positive surgical margin (p = 0.047), capsule invasion (p = 0.006) and biochemical recurrence (BCR) (p = 0.004). AR expression in the margin area of the tumour (M-AR) was associated with high Gleason score (p = 0.004), positive surgical margin (p = 0.004) and BCR (p = 0.05). M-TWIST overexpression was clearly associated with M-AR expression (p < 0.0001). Four parameters, i.e. M-TWIST overexpression (p < 0.0001), positive surgical margin (p = 0.003), high Gleason score (p < 0.0001) and M-AR expression (p = 0.008), predicted BFS. In the multivariate analysis, M-TWIST overexpression (p = 0.011) and Gleason score (p = 0.002) were the only independent predictors of BFS.
CONCLUSIONS: M-TWIST overexpression is associated with clinicopathological prognosis factors and M-AR overexpression and is a powerful independent predictor of BFS in conjunction with the Gleason score in prostate cancer patients treated with RP.

Entities:  

Keywords:  TWIST; androgen receptor; prognosis; prostate cancer; radical prostatectomy

Mesh:

Substances:

Year:  2014        PMID: 24779451     DOI: 10.3109/21681805.2014.909529

Source DB:  PubMed          Journal:  Scand J Urol        ISSN: 2168-1805            Impact factor:   1.612


  7 in total

1.  Anti-proliferation effects of Twist gene silencing in gastric cancer SGC7901 cells.

Authors:  Hui Zhang; Jian Gong; Di Kong; Hong-Yi Liu
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

2.  Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.

Authors:  Maahum Haider; Xiaotun Zhang; Ilsa Coleman; Nolan Ericson; Lawrence D True; Hung-Ming Lam; Lisha G Brown; Melanie Ketchanji; Belinda Nghiem; Bryce Lakely; Roger Coleman; Bruce Montgomery; Paul H Lange; Martine Roudier; Celestia S Higano; Jason H Bielas; Peter S Nelson; Robert L Vessella; Colm Morrissey
Journal:  Clin Exp Metastasis       Date:  2015-12-14       Impact factor: 5.150

3.  Deciphering the molecular mechanisms underlying the binding of the TWIST1/E12 complex to regulatory E-box sequences.

Authors:  Charlotte Bouard; Raphael Terreux; Mylène Honorat; Brigitte Manship; Stéphane Ansieau; Arnaud M Vigneron; Alain Puisieux; Léa Payen
Journal:  Nucleic Acids Res       Date:  2016-05-05       Impact factor: 16.971

4.  The epithelial-mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients.

Authors:  Astrid Børretzen; Karsten Gravdal; Svein A Haukaas; Monica Mannelqvist; Christian Beisland; Lars A Akslen; Ole J Halvorsen
Journal:  J Pathol Clin Res       Date:  2021-02-19

5.  LncRNA SNHG3 Promotes Gastric Cancer Cells Proliferation, Migration, and Invasion by Targeting miR-326.

Authors:  Jun Rao; Jinjin Fu; Chuchen Meng; Jin Huang; Xiangrong Qin; Shaohua Zhuang
Journal:  J Oncol       Date:  2021-06-28       Impact factor: 4.501

Review 6.  The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression.

Authors:  U-Ging Lo; Cheng-Fan Lee; Ming-Shyue Lee; Jer-Tsong Hsieh
Journal:  Int J Mol Sci       Date:  2017-09-30       Impact factor: 5.923

7.  Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer.

Authors:  Ning Xu; Hui-Jun Chen; Shao-Hao Chen; Xue-Yi Xue; Hong Chen; Qing-Shui Zheng; Yong Wei; Xiao-Dong Li; Jin-Bei Huang; Hai Cai; Xiong-Lin Sun
Journal:  Oncotarget       Date:  2016-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.